Metraipolis › archive › dc_bccf97ea44ad

GWAS identifies genetic loci for antibody response to SARS-CoV-2 vaccines in patients with systemic autoimmune diseases and healthy individuals — Europe PMC PPR:PPR1022439

Source: Europe PMC
Original: https://europepmc.org/article/PPR/PPR1022439
DOI: 10.1101/2025.05.16.25327770
License (as archived): CC0-1.0
Archived: 2026-10-06T10:17:14.246Z
SHA-256 of the archived text: 0b9c64b68e2d2604eba6bd47711413b9245135497fc74765b43dbb46b184e1de
Stable URL of this page: https://metraipolis.com/documento/dc_bccf97ea44ad

How to cite

GWAS identifies genetic loci for antibody response to SARS-CoV-2 vaccines in patients with systemic autoimmune diseases and healthy individuals — Europe PMC PPR:PPR1022439 — Europe PMC, https://europepmc.org/article/PPR/PPR1022439 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_bccf97ea44ad (Metraipolis archive dc_bccf97ea44ad, sha256 0b9c64b68e2d2604eba6bd47711413b9245135497fc74765b43dbb46b184e1de)

BibTeX

@misc{dcbccf97ea44ad,
  title = {GWAS identifies genetic loci for antibody response to SARS-CoV-2 vaccines in patients with systemic autoimmune diseases and healthy individuals — Europe PMC PPR:PPR1022439},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR1022439},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_bccf97ea44ad; sha256 0b9c64b68e2d2604eba6bd47711413b9245135497fc74765b43dbb46b184e1de},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR1022439. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The efficacy of nucleic acid-based vaccines against SARS-CoV-2 varies across individuals, partly due to genetic factors influencing neutralizing antibody production. In patients with systemic autoimmune diseases (SADs), this response may be further altered by immune dysregulation. We conducted a genome-wide association study (GWAS) to identify genetic variants associated with post-vaccination anti-SARS-CoV-2 IgG antibody levels and to assess whether these associations differ between SAD patients and healthy individuals. The study included 165 participants (138 with SADs, 27 healthy controls), all of whom received nucleic-acid based vaccines. Antibody levels targeting the spike protein receptor-binding domain (RBD) and nucleocapsid were measured between one and twelve months after vaccination. GWAS results were meta-analyzed with data from a previously published GWAS of 1,076 healthy individuals. We identified a novel association near RACGAP1 (rs706785; βmeta=–0.30, Pmeta=3.85×10−□) and replicated a known association at HLA-DRB1 position 71 (βmeta=–0.23, Pmeta=1.94×10 −11 ). No significant interactions were observed between genotype and disease status. This study highlights both MHC and non-MHC genetic contributions to SARS-CoV-2 vaccine responses and suggests these effects are consistent across SAD patients and healthy individuals, supporting standard vaccination strategies for individuals with systemic autoimmune conditions.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: medRxiv, 2025 (prima pubblicazione 2025-05-16).
Identificativi: DOI 10.1101/2025.05.16.25327770.
Pagina: https://europepmc.org/article/PPR/PPR1022439 — https://doi.org/10.1101/2025.05.16.25327770. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T09:45:27.643Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.